SynBiotic SE
XETRA SBX.DE
SynBiotic SE Revenue for the year ending December 31, 2023: USD 4.26 M
SynBiotic SE Revenue is USD 4.26 M for the year ending December 31, 2023, a -51.22% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
-
SynBiotic SE Revenue for the year ending December 31, 2022 was USD 8.74 M, a -15.32% change year over year.
-
SynBiotic SE Revenue for the year ending December 31, 2021 was USD 10.32 M, a 54.35% change year over year.
-
SynBiotic SE Revenue for the year ending December 31, 2020 was USD 6.68 M, a 0.00% change year over year.
-
SynBiotic SE Revenue for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.
Key data
| Date | Revenue | Gross Profit | Operating Income | EBIT |
|---|
Market news
Loading...
XETRA: SBX.DE
| CEO | Mr. Daniel Kruse |
| IPO Date | Jan. 7, 2021 |
| Location | Germany |
| Headquarters | Innere Wiener Str. 14 |
| Employees | 55 |
| Sector | Health Care |
| Industries | |
Description
SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email